ArticleCancer medicine2026
Integrated scRNA-Seq and Spatial Transcriptomics Reveal CHPF and GPC1 as Markers of Cancer-Associated Fibroblast-Dominant Domains in Colorectal Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Spatial heterogeneity in the colorectal cancer (CRC) tumor microenvironment (TME) is closely related to stromal organization and may influence treatment-related features. In this study, we integrated single-cell RNA sequencing and spatial transcriptomic data from CRC tissues to examine cancer-associated fibroblast (CAF)-dominant spatial domains. GPC1 and CHPF were enriched in stromal regions and showed higher expression in CRC tissues than in normal tissues. In the analyzed cohorts, higher GPC1 and CHPF expression was associated with advanced clinicopathological features and poorer survival outcomes in univariate analyses. Single-cell analyses showed that GPC1 and CHPF were mainly expressed in fibroblasts and were enriched in an ADAM12-associated fibroblast subset with myofibroblast-like features, extracellular matrix-related genes, and hypoxia/glycolysis-related signatures. Cell-cell communication analysis suggested that this fibroblast subset was linked to higher inferred WNT signaling. Drug-response and immunotherapy-related analyses further showed that GPC1 and CHPF expression was associated with transcriptomic patterns related to treatment response. In mucinous adenocarcinoma (MA), the ADAM12-associated fibroblast program showed stronger inferred MIF-related signaling and was associated with macrophage M2-like features. Spatial mapping and multiplex immunofluorescence supported partial colocalization of GPC1, CHPF, and ADAM12 in CAF-rich stromal regions. In CAFs, GPC1 or CHPF knockdown reduced ADAM12, CAF activation markers, and WNT/MIF-related proteins, while ADAM12 knockdown weakened macrophage M2-like marker expression in a co-culture model. These findings suggest that GPC1 and CHPF mark an ADAM12-associated CAF program linked to stromal remodeling and immune-related features in CRC, especially in MA, but further studies are needed to define its functional role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.